---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-086114"
form_type: "8-K"
ticker: "ANVS"
cik: "0001477845"
company_name: "Annovis Bio, Inc."
filed_at: "2024-08-06T23:59:59+00:00"
generated_at: "2026-05-31T12:13:58.919184+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Annovis Bio: buntanetap + GLP-1 agonist shows synergistic cognitive boost in AD mouse model

## Summary
- Combination of buntanetap and dulaglutide (Trulicity) restored cognitive function beyond healthy controls in Alzheimer's mouse model.
- Buntanetap alone restored to 100%, dulaglutide alone to 80%; combination showed 6-10x increase in efficacy.
- GLP-1 agonist dulaglutide was chosen for its good blood-brain barrier permeability among single-chain peptides.
- CEO Maria Maccecchini noted synergy could enhance treatment outcomes while minimizing side effects.

## SEC filing metadata
- accession: 0001104659-24-086114
- form_type: 8-K
- ticker: ANVS
- cik: 0001477845
- company_name: Annovis Bio, Inc.
- filed_at: 2024-08-06T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1477845/000110465924086114/0001104659-24-086114-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1477845/000110465924086114/tm2420928d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-086114
- JSON: https://secwatch.observer/filing/0001104659-24-086114.json
- Plain text: https://secwatch.observer/filing/0001104659-24-086114.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.